P&G fragrance deal
This article was originally published in The Rose Sheet
Executive Summary
Procter & Gamble Prestige Products will market and distribute Dolce & Gabbana fragrances under a multi-year licensing agreement with the Italian fashion label, firm announces. Companies plan to launch new beauty products globally upon the deal's July 1, 2006 effective date, P&G notes. Agreement, which includes D&G fragrances and all related products, is "in line with the P&G Beauty Corporate strategy to strengthen its core businesses and focus on higher-growth, higher-margin businesses," firm says. D&G's existing portfolio includes scents like Light Blue and Sicily for women. Brand previously was licensed by EuroItaly...
You may also be interested in...
Sales & Earnings In Brief
Procter & Gamble: Double-digit growth of P&G's prestige fragrances business was central to fourth-quarter and fiscal 2007 growth, according to an Aug. 3 release. Full-year net beauty sales increased 9% to $23.0 billion, firm says, attributing growth to Boss Selection and Boss Femme fragrance initiatives and the addition of Dolce & Gabbana's The One through a July 2006 licensing deal (1"The Rose Sheet" Dec. 19, 2005, In Brief). High single-digit skin-care growth was driven by Olay Definity and Regenerist, while hair-care sales increased by mid-single-digits on strong performances from Pantene, Head & Shoulders and Herbal Essences, P&G says. Q4 beauty sales totaled $5.9 bil., up 8%, with significant contributions coming from Escada and Lacoste within firm's prestige fragrances segment, as well as Dolce & Gabbana. Overall, company sales for the year rose 12% to $76.5 bil. Fourth-quarter revenue was up 8% to $19.3 bil. Double-digit increases in Blades & Razors and Health Care divisions were driven by sales of Gillette Fusion and Crest Pro-Health; Fiscal 2008 sales are expected to grow 5% to 7%...
P&G Beauty Grows On Fine Fragrances; Blades, Razors Drive Sales Overall
Prestige fragrance sales helped drive eight percent growth in Procter & Gamble's beauty business to $5.88 billion for the firm's fiscal year 2007 second quarter, ended Dec. 31, 2006, the company says
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.